JP Morgan Initiates Coverage On Kailera Therapeutics with Overweight Rating, Announces Price Target of $30
Benzinga Newsdesk 6 months ago
NewsPrice TargetInitiationAnalyst Ratings
JP Morgan analyst Hardik Parikh initiates coverage on Kailera Therapeutics (NASDAQ:KLRA) with a Overweight rating and announces Price Target of $30.
JP Morgan analyst Hardik Parikh initiates coverage on Kailera Therapeutics (NASDAQ:KLRA) with a Overweight rating and announces Price Target of $30.